Pharma Focus Asia

Beigene Plans to Construct New R&D and Manufacturing Sites in New Jersey


Beigene plans to Construct a new R&D Center and a manufacturing Center. The new site will be located at Princeton West Innovation Park in New Jersey.


The new manufacturing site is planned with an approximate area covering 42-acre site.

The start-of-the-art-facility features commercialstage biologic pharmaceutical manufacturing, clinical R&D, and center for pharmaovigilane innovation. Moreover, the site is designed to produce biologics and potentially small molecule cancer treatments.

With the expansion of the manufacturing facility, BeiGene expands its footprint in this region.

The new state-of-the-art manufacturing and clinical R&D center will help inbringing cancer medicines to patients across the globe.

Once the construction is done, it is expected that the new facility will hire hundrends of new employees in the areas of clinical research, development, regulatory, pharmacovigilance, and manufacturing.

With the existing presence of over 7,000 employees in Ridgefield Park along with the expansion intoPrinceton area will support in translating modern science into quality, innovative cancer therapies.

The construction of the new facility is expected to complete in the mid-2023.


TypeNew Construction
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference